EAU 2022

REVIEW UroToday

Viewing 1-20 of 57 articles

EAU 2022: A Phase III Study Comparing Diagnostic Accuracy of mpMRI Prostate to 18F-DCPyL PSMA PET/CT

EAU 2022: mpMRI vs 18F-DCPyL Discussant

EAU 2022: Discussant: Exploratory Endpoints from PROpel, a Phase III Trial of Abiraterone + Olaparib Versus Abiraterone + Placebo in First-Line mCRPC

EAU 2022: Exploratory Endpoints from PROpel: A Phase III Trial of Abiraterone + Olaparib Versus Abiraterone + Placebo in 1st Line mCRPC

New Imaging Technology Less Accurate than MRI at Detecting Prostate Cancer, Trial Shows

EAU 2022: How Should PET-Detected Oligorecurrent Prostate Cancer Best Be Treated? Metastasis-Directed Therapy

EAU 2022: How Should PET-Detected Oligorecurrent Prostate Cancer Best Be Treated? Systemic Therapy

EAU 2022: PSMA Theranostics and Novel Approaches to Treatment in mCRPC

EAU 2022: Management of De Novo mHSPC with Oligometastases (cT3cN+cM1a): Targeted Therapy of the Primary and Metastases Is the Way to Go

EAU 2022: State of the Art Lecture: mHSPC - Doublet vs Triplet Combination Therapy

EAU 2022: Overall Survival With Darolutamide Versus Placebo in Combination With Androgen Deprivation Therapy and Docetaxel by Stratification Factors in the Phase 3 ARASENS Trial

EAU 2022: Phase 3 ARASENS Trial Discussion - Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

EAU 2022: State of the Art Lecture: Future Perspectives in the Management of mHSPC: Where Are We Heading To?

EAU 2022: Management of De Novo mHSPC With Oligometastases (cT3cN+cM1a): Systemic Combination Therapy Is the Best Approach

Only Through International Cooperation Can AI Improve Patient Lives

EAU 2022: Lifetime Risk of Prostate Cancer Death Among High-Risk Germline Mutation Carriers

EAU 2022: Impact of Non-Muscle Invasive Bladder Cancer Treatment History on the Efficacy of Pembrolizumab for Patients with Metastatic Urothelial Carcinoma

EAU 2022: First Line Avelumab in PD-L1+ve Metastatic or Locally Advanced Urothelial Cancer (aUC) Patients Unfit for Cisplatin: The ARIES Trial

EAU 2022: State of the Art Lecture: Synchronous vs Metachronous mHSPC: What makes the difference?

EAU 2022: BRCA1/2 and ATM Mutated Metastatic Prostate Cancers May Present With Low Serum PSA

1
2
3